Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease: Brief Definitive Report

Parasite Immunology

Volumn 32, Issue 6, 2010, Pages 464-469

  Olivieri, B P ^a,b   Vasconcellos, R ^c   Nobrega A ^d   Minoprio, P ^e   Kaveri, S V ^f,g,h   Araujo Jorge T C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Fundacao de Apoio a Escola Tecnica   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUT PASTEUR   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSERM   (France)

Author keywords

Acute phase; Chagas disease; Intravenous immunoglobulin; Mice

Indexed keywords

IMMUNOGLOBULIN;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TIME FACTORS;

MUS; TRYPANOSOMA CRUZI;

EID: 77952273780     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2010.01212.x     Document Type: Article

References (44)

1. Moncayo A Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009 104 (Suppl. I 17 30.
2. Rassi A Jr., Rassi A Marin-Neto JA. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 2009 104 (Suppl. I 152 158.
3. Jannin J Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz 2007 102 (Suppl. 1 95 97.
4. Villa L, Morote S, Bernal O, Bulla D Albajar-Vinas P. Access to diagnosis and treatment of Chagas disease/infection in endemic and non-endemic countries in the XXI century. Mem Inst Oswaldo Cruz 2007 102 (Suppl. 1 87 94.
5. Araújo-Jorge T. Doença de Chagas: Manual para experimentação animal.
6. D'Imperio Lima MR, Eisen H, Minoprio P, Joskowicz M Coutinho A. Persistence of polyclonal B cell activation with undetectable parasitaemia in late stages of experimental Chagas' disease. J Immunol 1986 137 : 353 356.
7. Minoprio P, Burlen O, Pereira P, et al. Most B cells in acute Trypanosoma cruzi infection lack parasite specificity. Scand J Immunol 1988 28 : 553 561.
8. Minoprio PM, Coutinho A, Joskowicz M, D'Imperio Lima MR Eisen H. Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. II. Cytotoxic T lymphocytes. Scand J Immunol 1986 24 : 669 679. (Pubitemid 17212846)
9. Minoprio PM, Eisen H, Forni L, D'Imperio Lima MR, Joskowicz M Coutinho A. Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. I. Quantitation of both T- and B-cell responses. Scand J Immunol 1986 24 : 661 668. (Pubitemid 17212845)
10. Bonney KM Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 2008 8 : 510 518.
11. Marin-Neto JA, Cunha-Neto E, Maciel BC Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007 115 : 1109 1123.
12. Kazatchkine MD Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 345 : 747 755.
13. Arnson Y, Shoenfeld Y Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009 42 : 553 560.
14. Nimmerjahn F Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008 26 : 513 533.
15. Sibéril S, Elluru S, Graff-Dubois S, et al. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann NY Acad Sci 2007 1110 : 497 506. (Pubitemid 350043039)
16. Mouthon L Lortholary O. Intravenous immunoglobulins in infectious diseases: where do we stand? Clin Microbiol Infect 2003 9 : 333 338.
17. Roy E, Stavropoulos E, Brennan J, et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005 73 : 6101 6109.
18. Nussinovitch U Shoenfeld Y. Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008 7 : 445 452.
19. Aukrust P, Yndestad A, Ueland T, Damås JK, Frøland SS Gullestad L. The role of intravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol 2006 112 : 40 45.
20. Kishimoto C, Takamatsu N, Kawamata H, Shinohara H Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol 2000 36 : 1979 1984.
21. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001 103 : 220 225. (Pubitemid 32095406)
22. Santos-Lima EC, Vasconcellos R, Reina-San-Martin B, et al. Significant association between the skewed natural antibody repertoire of Xid mice and resistance to Trypanosoma cruzi infection. Eur J Immunol 2001 31 : 634 645.
23. Oliveira GM, Diniz RL, Batista W, et al. Fas ligand-dependent inflammatory regulation in acute myocarditis induced by Trypanosoma cruzi infection. Am J Pathol 2007 171 : 79 86.
24. Kaneko Y, Nimmerjahn F Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 313 : 670 673.
25. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002 46 : 1689 1690.
26. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008 111 : 715 722.
27. Malanchere E, Marcos MA, Nobrega A Coutinho A. Studies on the T cell dependence of natural IgM and IgG antibody repertoires in adult mice. Eur J Immunol 1995 25 : 1358 1365.
28. Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008 7 : 440 444.
29. Spinella S, Milon G Hontebeyrie-Joskowicz M. A CD4 + Th2 cell line isolated from mice chronically infected with Trypanosoma cruzi induces IgG2 polyclonal response in vivo. Eur J Immunol 1990 20 : 1045 1051.
30. Reina-San-Martin B, Degrave W, Rougeot C, et al. B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. Nat Med 2000 6 : 890 897.
31. Gao W, Wortis HH Pereira MA. The Trypanosoma cruzi trans-sialidase is a T cell-independent B cell mitogen and an inducer of non-specific Ig secretion. Int Immunol 2002 14 : 299 308.
32. Montes CL, Vottero-Cima E Gruppi A. Trypanosoma cruzi cytosolic alkaline antigens (FI) induce polyclonal activation in murine normal B cells. Scand J Immunol 1996 44 : 93 100.
33. Grauert MR, Houdayer M Hontebeyrie-Joskowciz M. Trypanosoma cruzi infection enhances polyreactive antibody response in an acute case of human Chagas' disease. Clin Exp Immunol 1993 93 : 85 92.
34. Krettli AU. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives. Mem Inst Oswaldo Cruz 2009 104 (Suppl. 1 142 151.
35. Truyens C, Torrico F, Angelo-Barrios A, et al. The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol 1995 17 : 561 568.
36. Oliveira GM, da Silva TM, Batista WS, Franco M Schor N. Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice. Parasitol Res 2009 106 : 111 120.
37. Gutierrez FR, Mineo TW, Pavanelli WR, Guedes PM Silva JS. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 2009 104 (Suppl. 1 236 245.
38. World Health Organization. Report of the Scientific Working Group on Chagas Disease, Buenos Aires, Argentina 17-20 April 2005: summary and recommendations. In: http://www.who.int/tdr/diseases/swg-chagas.pdf, Last access April 26th 2007.
39. Chamond N, Coatnoan N Minoprio P. Immunotherapy of Trypanosoma cruzi infections. Curr Drug Targets Immune Endocr Metabol Disord 2002 2 : 247 254.
40. Waghabi MC, Souza EM, Oliveira GM, et al. Pharmacological inhibition of Transforming Growth Factor β signaling decreases infection and prevents heart damage in acute Chagas' disease. Antimicrob Agents Chemother 2009 53 : 4694 4701.
41. Medeiros GA, Silvério JC, Marino AP, et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect 2009 11 : 264 273.
42. Lannes-Vieira J, Silverio JC, Pereira IR, et al. Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokine receptors - how to make a dream come true. Mem Inst Oswaldo Cruz 2009 104 (Suppl. 1 226 235.
43. Krause I, Wu R, Sherer Y, Patanik M, Peter JB Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002 12 : 133 139.
44. Bayry J, Lacroix-Desmazes S, Kazatchkine MD Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 2004 25 : 306 310.